

# Ian Chau

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7317812/publications.pdf>

Version: 2024-02-01

498  
papers

34,231  
citations

14644

66  
h-index

4223

174  
g-index

516  
all docs

516  
docs citations

516  
times ranked

33286  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 337-345.	13.9	4,721
2	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
3	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2014, 383, 31-39.	6.3	1,833
4	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	13.9	1,483
5	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018, 359, 920-926.	6.0	1,199
6	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 883-895.	5.1	1,091
7	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	6.3	984
8	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 801-810.	5.1	719
9	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5513-5518.	0.8	708
10	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 859-870.	5.1	699
11	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv238-iv255.	0.6	663
12	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 481-489.	5.1	631
13	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	0.8	580
14	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 78-86.	5.1	516
15	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2836-2844.	0.8	459
16	Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancer—Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data. <i>Journal of Clinical Oncology</i> , 2004, 22, 2395-2403.	0.8	455
17	Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging—Defined Poor-Risk Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 668-674.	0.8	432
18	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2022, 386, 449-462.	13.9	419

#	ARTICLE	IF	CITATIONS
19	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). <i>Journal of Clinical Oncology</i> , 2012, 30, 1620-1627.	0.8	357
20	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 749-759.	5.1	333
21	Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , The, 2010, 11, 241-248.	5.1	305
22	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
23	Vemurafenib for <i>BRAF</i> <sup>V600E</sup> Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. <i>JAMA Oncology</i> , 2018, 4, 384.	3.4	280
24	Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. <i>Annals of Oncology</i> , 2015, 26, 702-708.	0.6	271
25	BRAF Inhibition in <i>BRAF</i> <sup>V600E</sup> -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3477-3484.	0.8	247
26	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	0.5	241
27	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	3.0	223
28	High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. <i>Cancer Discovery</i> , 2016, 6, 838-851.	7.7	222
29	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. <i>Annals of Oncology</i> , 2011, 22, 2042-2048.	0.6	197
30	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	5.1	193
31	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	5.1	191
32	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. <i>Cancer Discovery</i> , 2018, 8, 1270-1285.	7.7	187
33	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. <i>JAMA Oncology</i> , 2021, 7, 895.	3.4	184
34	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 36, 35-50.e9.	7.7	179
35	Guidance on the management of diarrhoea during cancer chemotherapy. <i>Lancet Oncology</i> , The, 2014, 15, e447-e460.	5.1	171
36	A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. <i>Annals of Oncology</i> , 2005, 16, 549-557.	0.6	168

#	ARTICLE	IF	CITATIONS
37	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. <i>British Journal of Cancer</i> , 2009, 101, 1033-1038.	2.9	154
38	The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1420-1429.	0.8	153
39	Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. <i>Trials</i> , 2016, 17, 17.	0.7	148
40	Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. <i>European Radiology</i> , 2008, 18, 903-910.	2.3	145
41	Adjuvant therapy in colon cancer—what, when and how?. <i>Annals of Oncology</i> , 2006, 17, 1347-1359.	0.6	142
42	Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3130-3136.	0.8	132
43	Targeting the human EGFR family in esophagogastric cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 492-503.	12.5	132
44	Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. <i>British Journal of Cancer</i> , 2014, 110, 19-25.	2.9	130
45	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , 2018, 23, 1407-e136.	1.9	127
46	Evaluating Mesorectal Lymph Nodes in Rectal Cancer Before and After Neoadjuvant Chemoradiation Using Thin-Section T2-Weighted Magnetic Resonance Imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 456-461.	0.4	126
47	Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2009, 4, 54-72.	0.8	125
48	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	5.7	123
49	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 3978-3992.	0.8	121
50	Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 3945-3950.	0.8	118
51	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 1478-1485.	2.9	118
52	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
53	Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2279-2287.	0.8	100
54	Does surgery have a role in managing incurable gastric cancer?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 676-682.	12.5	96

#	ARTICLE	IF	CITATIONS
55	Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. <i>Annals of Oncology</i> , 2017, 28, 2932-2942.	0.6	93
56	Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020, 10, 657-663.	7.7	93
57	Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. <i>Haematologica</i> , 2007, 92, 271-272.	1.7	90
58	Treatment in advanced colorectal cancer: what, when and how?. <i>British Journal of Cancer</i> , 2009, 100, 1704-1719.	2.9	89
59	MRI-Diagnosed Tumor Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer. <i>Annals of Surgery</i> , 2022, 276, 334-344.	2.1	86
60	EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. <i>Annals of Oncology</i> , 2014, 25, 858-863.	0.6	85
61	Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2015, 26, 804-811.	0.6	83
62	Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5875-5881.	3.2	82
63	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 183-192.	3.2	79
64	Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. <i>British Journal of Cancer</i> , 2003, 88, 1017-1024.	2.9	78
65	Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. <i>British Journal of Cancer</i> , 2003, 88, 1859-1865.	2.9	78
66	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 235.	3.4	74
67	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 933-946.	3.7	73
68	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. <i>Gastric Cancer</i> , 2022, 25, 197-206.	2.7	72
69	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. <i>British Journal of Cancer</i> , 2006, 94, 1107-1115.	2.9	71
70	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. <i>Nature Medicine</i> , 2021, 27, 1362-1366.	15.2	70
71	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. <i>British Journal of Cancer</i> , 2003, 89, 36-42.	2.9	68
72	Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. <i>British Journal of Cancer</i> , 2004, 91, 1453-1458.	2.9	67

#	ARTICLE	IF	CITATIONS
73	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	5.7	66
74	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
75	Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA4001-LBA4001.	0.8	65
76	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1557-1565.	0.6	64
77	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. <i>European Journal of Cancer</i> , 2017, 81, 17-25.	1.3	64
78	MRI Predictive Factors for Tumor Response in Rectal Cancer Following Neoadjuvant Chemoradiation Therapy - Implications for Induction Chemotherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 505-511.	0.4	63
79	FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. <i>Clinical Colorectal Cancer</i> , 2014, 13, 232-238.	1.0	60
80	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. <i>Gut</i> , 2018, 67, 1484-1492.	6.1	59
81	An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2001, 115, 786-792.	1.2	58
82	Timing of Surgery Following Preoperative Therapy in Rectal Cancer: The Need for a Prospective Randomized Trial?. <i>Diseases of the Colon and Rectum</i> , 2011, 54, 1251-1259.	0.7	58
83	Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2003, 120, 970-977.	1.2	56
84	Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. <i>British Journal of Cancer</i> , 2005, 92, 1352-1357.	2.9	56
85	PD-1 and PD-L1 blockade in gastrointestinal malignancies. <i>Cancer Treatment Reviews</i> , 2015, 41, 893-903.	3.4	55
86	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. <i>Scientific Reports</i> , 2018, 8, 1445.	1.6	55
87	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3926-3935.	3.2	55
88	Longitudinal Assessment of Quality of Life in Rectal Cancer Patients With or Without Stomas Following Primary Resection. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 669-677.	0.7	54
89	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017, 17, 132.	0.9	54
90	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. <i>British Journal of Cancer</i> , 2016, 115, 974-982.	2.9	53



#	ARTICLE	IF	CITATIONS
91	Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.. Journal of Clinical Oncology, 2017, 35, 4014-4014.	0.8	53
92	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160.	5.1	51
93	The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology, 2009, 20, 885-891.	0.6	50
94	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematology, the, 2018, 5, e190-e200.	2.2	50
95	CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).. Journal of Clinical Oncology, 2016, 34, 4010-4010.	0.8	50
96	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeneity and convergent evolution. Critical Reviews in Oncology/Hematology, 2019, 143, 153-163.	2.0	49
97	Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).. Journal of Clinical Oncology, 2017, 35, 709-709.	0.8	49
98	Adjuvant therapy in colon cancer: current status and future directions. Cancer Treatment Reviews, 2002, 28, 223-236.	3.4	48
99	Optimal Management of Gastric Cancer. Annals of Surgery, 2014, 259, 102-108.	2.1	48
100	Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone?. World Journal of Gastroenterology, 2014, 20, 12391.	1.4	48
101	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. ESMO Open, 2020, 5, e000638.	2.0	47
102	Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study. Journal of Clinical Oncology, 2009, 27, e3-e4.	0.8	46
103	The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Annals of Oncology, 2010, 21, 1013-1019.	0.6	46
104	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. Journal of the National Cancer Institute, 2014, 106, .	3.0	46
105	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Clinical Chemistry, 2018, 64, 1626-1635.	1.5	46
106	Novel STAT 3 inhibitors for treating gastric cancer. Expert Opinion on Investigational Drugs, 2016, 25, 1023-1031.	1.9	45
107	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clinical Colorectal Cancer, 2018, 17, e69-e76.	1.0	44
108	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 115-122.e2.	1.0	43

#	ARTICLE	IF	CITATIONS
109	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. <i>European Journal of Cancer</i> , 2019, 121, 40-47.	1.3	43
110	A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor-Resistant Advanced Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3023-3031.	0.8	42
111	The genomic landscape of oesophagogastric junctional adenocarcinoma. <i>Journal of Pathology</i> , 2013, 231, 301-310.	2.1	42
112	Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. <i>Journal of the American College of Surgeons</i> , 2013, 217, 347-357e1.	0.2	42
113	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3830-3838.	3.2	42
114	The vital role of education and information in patients receiving capecitabine (Xeloda®). <i>European Journal of Oncology Nursing</i> , 2004, 8, S41-S53.	0.9	38
115	Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. <i>European Journal of Cancer</i> , 2013, 49, 2116-2125.	1.3	38
116	Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. <i>European Journal of Cancer Care</i> , 2013, 22, 714-725.	0.7	38
117	Folate Metabolism Polymorphisms Influence Risk of Colorectal Adenoma Recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1607-1613.	1.1	36
118	Processes of Care in the Multidisciplinary Treatment of Gastric Cancer. <i>JAMA Surgery</i> , 2014, 149, 18.	2.2	36
119	Management of resectable colorectal lung metastases. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 285-296.	1.7	36
120	Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience. <i>BMC Cancer</i> , 2015, 15, 15.	1.1	35
121	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 289-298.	0.5	35
122	Chemotherapy in colorectal cancer: new options and new challenges. <i>British Medical Bulletin</i> , 2002, 64, 159-180.	2.7	34
123	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. <i>Oncotarget</i> , 2016, 7, 12672-12681.	0.8	34
124	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. <i>International Journal of Cancer</i> , 2020, 146, 94-102.	2.3	34
125	A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA4000-LBA4000.	0.8	34
126	Pancreatic neuroendocrine tumors: a review. <i>Future Oncology</i> , 2015, 11, 853-864.	1.1	33



#	ARTICLE	IF	CITATIONS
127	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 280-284.	1.0	33
128	Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. <i>European Journal of Cancer</i> , 2019, 107, 115-123.	1.3	33
129	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6-6.	0.8	33
130	Overview of Preoperative and Postoperative Therapy for Colorectal Cancer: The European and United States Perspectives. <i>Clinical Colorectal Cancer</i> , 2003, 3, 19-33.	1.0	32
131	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. <i>Annals of Oncology</i> , 2013, 24, 3123-3128.	0.6	32
132	The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. <i>British Journal of Radiology</i> , 2013, 86, 20130281.	1.0	32
133	A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. <i>BMC Cancer</i> , 2014, 14, 605.	1.1	32
134	Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. <i>BMC Cancer</i> , 2015, 15, 764.	1.1	32
135	A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. <i>European Journal of Cancer</i> , 2019, 108, 17-24.	1.3	32
136	Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2508-2508.	0.8	32
137	Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naïve advanced colorectal cancer: a phase II study. <i>Annals of Oncology</i> , 2007, 18, 730-737.	0.6	31
138	Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. <i>Oncologist</i> , 2017, 22, 402-408.	1.9	31
139	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	31
140	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1 positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4503-4503.	0.8	31
141	Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. <i>British Journal of Cancer</i> , 2012, 106, 1718-1721.	2.9	30
142	Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. <i>European Journal of Cancer</i> , 2011, 47, 1146-1151.	1.3	29
143	RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial. <i>European Journal of Cancer</i> , 2014, 50, 1430-1436.	1.3	29
144	Cyclooxygenase Inhibition in Cancer – A Blind Alley or a New Therapeutic Reality?. <i>New England Journal of Medicine</i> , 2002, 346, 1085-1087.	13.9	28

#	ARTICLE	IF	CITATIONS
145	Patupilone in cancer treatment. Expert Opinion on Investigational Drugs, 2011, 20, 107-117.	1.9	28
146	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European Journal of Cancer, 2014, 50, 1422-1429.	1.3	28
147	A Pilot Study Assessing the Incidence and Clinical Significance of Circulating Tumor Cells in Esophagogastric Cancers. Clinical Colorectal Cancer, 2014, 13, 94-99.	1.0	28
148	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. British Journal of Cancer, 2018, 119, 19-26.	2.9	28
149	Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, Tj ETQq1 1 0.7843 14 rgB14 Overlook	1.0	28
150	Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?. Clinical Colorectal Cancer, 2016, 15, e53-e59.	1.0	27
151	Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. Clinical Colorectal Cancer, 2018, 17, 223-230.	1.0	27
152	Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. BMC Cancer, 2012, 12, 326.	1.1	26
153	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. Clinical Cancer Research, 2017, 23, 6002-6011.	3.2	26
154	Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. British Journal of Cancer, 2001, 85, 1258-1264.	2.9	25
155	Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. Cancers, 2019, 11, 1558.	1.7	25
156	Molecular target: pan-AKT in gastric cancer. ESMO Open, 2020, 5, e000728.	2.0	25
157	Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. ESMO Open, 2020, 5, e000791.	2.0	25
158	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treatment Reviews, 2020, 86, 101998.	3.4	25
159	Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. Current Drug Targets, 2016, 18, 56-71.	1.0	25
160	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of Oncology, 2015, 26, 1936-1941.	0.6	24
161	Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?. Lancet, The, 2017, 390, 2418-2419.	6.3	24
162	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. Oncologist, 2018, 23, 822-839.	1.9	24

#	ARTICLE	IF	CITATIONS
163	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. <i>Gut</i> , 2021, 70, 1632-1641.	6.1	24
164	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. <i>Gut</i> , 2021, 70, 1904-1913.	6.1	24
165	LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. <i>Annals of Oncology</i> , 2021, 32, S1332.	0.6	24
166	Matrix metalloproteinase inhibitors— an emphasis on gastrointestinal malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 151-176.	2.0	23
167	Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5499-5505.	0.8	23
168	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. <i>Annals of Oncology</i> , 2012, 23, 119-127.	0.6	23
169	Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection. <i>Clinical Colorectal Cancer</i> , 2013, 12, 15-22.	1.0	22
170	Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 373-383.	1.4	22
171	Gastric Cancer — From Aetiology to Management: Differences Between the East and the West. <i>Clinical Oncology</i> , 2019, 31, 570-577.	0.6	22
172	A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). <i>European Journal of Cancer</i> , 2013, 49, 3507-3516.	1.3	21
173	Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. <i>Annals of the Royal College of Surgeons of England</i> , 2014, 96, 543-546.	0.3	21
174	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 303-312.	0.4	21
175	Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. <i>Annals of Oncology</i> , 2018, 29, 230-236.	0.6	21
176	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). <i>Heliyon</i> , 2018, 4, e00804.	1.4	21
177	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020, 12, 2985.	1.7	21
178	Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 3523-3523.	0.8	21
179	Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).. <i>Journal of Clinical Oncology</i> , 2018, 36, 101-101.	0.8	21
180	Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. <i>European Journal of Cancer</i> , 2005, 41, 1551-1559.	1.3	20

#	ARTICLE	IF	CITATIONS
181	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. <i>British Journal of Cancer</i> , 2009, 100, 1725-1730.	2.9	20
182	Preoperative and Postoperative Chemotherapy for Gastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 99-112.	0.6	20
183	The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: An exploratory study. <i>European Journal of Surgical Oncology</i> , 2015, 41, 484-492.	0.5	20
184	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF <sup>V600</sup> Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	1.5	20
185	Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 102-102.	0.8	20
186	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3518-3518.	0.8	20
187	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2017, 35, 102-102.	0.8	20
188	CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS192-TPS192.	0.8	20
189	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 430-430.	0.8	20
190	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. <i>Gut</i> , 2018, 67, 1780-1792.	6.1	19
191	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5-5.	0.8	19
192	Gemcitabine and Its Combinations in the Treatment of Malignant Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 97-104.	2.1	18
193	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 814-824.	1.4	18
194	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. <i>ESMO Open</i> , 2020, 5, e000797.	2.0	18
195	A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3056-3056.	0.8	18
196	Mucosa associated lymphoid tissue lymphoma of the lung: The Royal Marsden Hospital experience. <i>Leukemia and Lymphoma</i> , 2007, 48, 547-550.	0.6	17
197	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014, 50, 3136-3144.	1.3	17
198	Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 112.	1.1	17

#	ARTICLE	IF	CITATIONS
199	Claudin 18.2â€™ a FAST-moving target in gastric cancer?. <i>Annals of Oncology</i> , 2021, 32, 584-586.	0.6	17
200	Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC). <i>Cancer Research</i> , 2019, 79, 2673-2673.	0.4	17
201	Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom.. <i>Journal of Clinical Oncology</i> , 2011, 29, 489-489.	0.8	17
202	CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS193-TPS193.	0.8	17
203	Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. <i>British Journal of Cancer</i> , 2003, 88, 1510-1515.	2.9	16
204	The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. <i>Clinical Nuclear Medicine</i> , 2015, 40, e259-e264.	0.7	16
205	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. <i>Oncologist</i> , 2016, 21, 1502-1508.	1.9	16
206	ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. <i>Clinical Colorectal Cancer</i> , 2019, 18, 280-291.e5.	1.0	16
207	Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). <i>Clinical Colorectal Cancer</i> , 2019, 18, 183-191.e3.	1.0	16
208	Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 32-38.e3.	1.0	16
209	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. <i>Nature Ecology and Evolution</i> , 2021, 5, 1024-1032.	3.4	16
210	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA5-LBA5.	0.8	16
211	CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS212-TPS212.	0.8	16
212	What studies are appropriate and necessary for staging gastric adenocarcinoma? Results of an international RAND/UCLA expert panel. <i>Gastric Cancer</i> , 2014, 17, 377-382.	2.7	15
213	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016, 37, 852-857.	1.3	15
214	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. <i>Cancers</i> , 2019, 11, 736.	1.7	15
215	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. <i>Cancer Treatment Reviews</i> , 2019, 73, 31-40.	3.4	15
216	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 133-141.	2.7	15



#	ARTICLE	IF	CITATIONS
217	Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. Journal of Clinical Oncology, 2016, 34, 154-154.	0.8	15
218	Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, TPS213-TPS213.	0.8	15
219	Oxaliplatin for Colorectal Cancer in the United States: Better Late Than Never. Journal of Clinical Oncology, 2003, 21, 2049-2051.	0.8	14
220	6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. European Journal of Cancer, Supplement, 2009, 7, 344-345.	2.2	14
221	What provider volumes and characteristics are appropriate for gastric cancer resection? Results of an international RAND/UCLA expert panel. Surgery, 2013, 154, 1100-1109.	1.0	14
222	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. European Radiology, 2020, 30, 6702-6708.	2.3	14
223	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. Cancers, 2020, 12, 657.	1.7	14
224	Targeting the Stroma in the Management of Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 691185.	1.3	14
225	COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, LBA4-LBA4.	0.8	14
226	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated $\alpha$ -fetoprotein (AFP) from the randomized phase III REACH study.. Journal of Clinical Oncology, 2015, 33, 232-232.	0.8	14
227	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.. Journal of Clinical Oncology, 2017, 35, 4046-4046.	0.8	14
228	POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer – A phase III randomized study.. Journal of Clinical Oncology, 2019, 37, TPS3615-TPS3615.	0.8	14
229	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. Oncotarget, 2017, 8, 64999-65008.	0.8	14
230	Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology, 2007, 12, 149-153.	0.7	13
231	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003 – 2013. Leukemia and Lymphoma, 2017, 58, 1805-1813.	0.6	13
232	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clinical Cancer Research, 2020, 26, 3546-3556.	3.2	13
233	Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).. Journal of Clinical Oncology, 2014, 32, 4016-4016.	0.8	13
234	Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget, 2018, 9, 36654-36665.	0.8	13



#	ARTICLE	IF	CITATIONS
235	Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. <i>British Journal of Cancer</i> , 2011, 104, 43-50.	2.9	12
236	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2012, 23, 942-947.	0.6	12
237	A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2013, 20, 533-541.	0.7	12
238	Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies. <i>Oncologist</i> , 2013, 18, 833-842.	1.9	12
239	The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 1443-1453.	1.0	12
240	VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2533-2533.	0.8	12
241	HER2 targeted therapy in colorectal cancer: New horizons. <i>Cancer Treatment Reviews</i> , 2022, 105, 102363.	3.4	12
242	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2015, 94, 219-226.	1.1	11
243	Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. <i>Drugs</i> , 2016, 76, 13-26.	4.9	11
244	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMJ Open</i> , 2020, 10, e034527.	0.8	11
245	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. <i>European Journal of Cancer</i> , 2020, 135, 103-112.	1.3	11
246	386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2021, 32, S532.	0.6	11
247	Bevacizumab-associated gastrointestinal perforation. <i>Lancet Oncology</i> , The, 2009, 10, 534-536.	5.1	10
248	Immunotherapy for oesophagogastric cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1197-1207.	1.4	10
249	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. <i>Oncologist</i> , 2017, 22, 728-736.	1.9	10
250	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. <i>Leukemia and Lymphoma</i> , 2018, 59, 1586-1595.	0.6	10
251	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 159-171.	0.8	10
252	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. <i>Clinical Colorectal Cancer</i> , 2019, 18, 64-71.e1.	1.0	10

#	ARTICLE	IF	CITATIONS
253	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. Journal of Clinical Oncology, 2021, 39, TPS3620-TPS3620.	0.8	10
254	Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3114-TPS3114.	0.8	10
255	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with <i>BRAF</i> <sup>V600</sup> mutation.. Journal of Clinical Oncology, 2017, 35, 9074-9074.	0.8	10
256	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	5.8	10
257	Impact of 5-Fluorouracil Rechallenge on Subsequent Response and Survival in Advanced Colorectal Cancer: Pooled Analysis from Three Consecutive Randomized Controlled Trials. Clinical Colorectal Cancer, 2003, 3, 102-107.	1.0	9
258	Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. British Journal of Cancer, 2010, 102, 255-261.	2.9	9
259	Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer. Pancreas, 2013, 42, 511-515.	0.5	9
260	Neoadjuvant rectal score: run with the hare and hunt with the hounds. Annals of Oncology, 2018, 29, 2261-2262.	0.6	9
261	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. Frontiers in Oncology, 2019, 9, 618.	1.3	9
262	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Current Problems in Cancer, 2019, 43, 487-494.	1.0	9
263	A phase I/II study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Advances, 2021, 5, 4073-4082.	2.5	9
264	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. Blood, 2015, 126, 4263-4263.	0.6	9
265	Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. Seminars in Radiation Oncology, 2011, 21, 196-202.	1.0	8
266	Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Investigational New Drugs, 2013, 31, 1339-1344.	1.2	8
267	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Annals of Hematology, 2014, 93, 827-834.	0.8	8
268	Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial. Translational Gastroenterology and Hepatology, 2016, 1, 46-46.	1.5	8
269	Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010. Gastric Cancer, 2016, 19, 1114-1124.	2.7	8
270	Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma. Hematology/Oncology Clinics of North America, 2017, 31, 529-544.	0.9	8

#	ARTICLE	IF	CITATIONS
271	The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 52-59.	1.2	8
272	Ramucirumab and its use in the treatment of hepatocellular carcinoma. <i>Future Oncology</i> , 2019, 15, 979-988.	1.1	8
273	Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases. <i>American Journal of Roentgenology</i> , 2021, 216, 669-676.	1.0	8
274	Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 201-201.	0.8	8
275	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. <i>Blood</i> , 2016, 128, 624-624.	0.6	8
276	EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3513-3513.	0.8	8
277	TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancerâ€”A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4120-TPS4120.	0.8	8
278	Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 59-78.	1.9	8
279	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 821-833.	0.6	8
280	Neoadjuvant therapy before surgical treatment. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 45-59.	2.2	7
281	An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 1228-1235.	1.2	7
282	<i>FCÎ³R11a</i> and <i>FCÎ³R11a</i> Polymorphisms and Cetuximab Benefit in the Microscopic Disease. <i>Clinical Cancer Research</i> , 2014, 20, 4511-4519.	3.2	7
283	REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancerâ€”Response rate (RR), toxicity, and molecular analysis from phase II.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4131-4131.	0.8	7
284	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 3575-3575.	0.8	7
285	Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 658-658.	0.8	7
286	Capecitabine in gastric cancer. <i>Drugs of Today</i> , 2008, 44, 629.	0.7	7
287	Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 333.	0.8	7
288	Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 613-613.	0.8	7

#	ARTICLE	IF	CITATIONS
289	Trastuzumab for gastric cancer treatment. <i>Lancet</i> , The, 2010, 376, 1736.	6.3	6
290	Ramucirumab: targeting angiogenesis in the treatment of gastric cancer. <i>Immunotherapy</i> , 2014, 6, 1177-1186.	1.0	6
291	Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine Practice. <i>Seminars in Radiation Oncology</i> , 2016, 26, 176-185.	1.0	6
292	Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 104-112.	1.4	6
293	Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies. <i>Clinical Colorectal Cancer</i> , 2017, 16, e181-e189.	1.0	6
294	Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. <i>BMC Hematology</i> , 2018, 18, 19.	2.6	6
295	Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer?. <i>Annals of Oncology</i> , 2019, 30, 159-161.	0.6	6
296	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. <i>Annals of Hematology</i> , 2020, 99, 105-112.	0.8	6
297	O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. <i>Annals of Oncology</i> , 2020, 31, 236.	0.6	6
298	Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4015-4015.	0.8	6
299	Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1159-1167.	1.4	6
300	MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS530-TPS530.	0.8	6
301	Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 589-597.	1.0	6
302	Primary Follicular Lymphoma of the GI Tract: An Increasingly Recognized Entity. <i>Journal of Clinical Oncology</i> , 2012, 30, e370-e372.	0.8	5
303	The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. <i>European Journal of Cancer</i> , 2015, 51, 2732-2739.	1.3	5
304	Beyond genomics â€“ Targeting the epigenome in diffuse large B-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2017, 59, 132-137.	3.4	5
305	Session 3: Beyond <sc>TME</sc> and radiotherapy <sc>MRI</sc> evaluation of rectal cancer treatment response. <i>Colorectal Disease</i> , 2018, 20, 76-81.	0.7	5
306	Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 103-114.	0.6	5

#	ARTICLE	IF	CITATIONS
307	Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. BMC Gastroenterology, 2020, 20, 133.	0.8	5
308	A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas. Advances in Therapy, 2021, 38, 707-720.	1.3	5
309	443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers â€” phase IIA dose finding. Annals of Oncology, 2021, 32, S555-S556.	0.6	5
310	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. Journal of Clinical Medicine, 2021, 10, 215.	1.0	5
311	Rare case of cerebral MALToma presenting with stroke-like symptoms and seizures. BMJ Case Reports, 2013, 2013, bcr2012008494-bcr2012008494.	0.2	5
312	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. Blood, 2016, 128, 480-480.	0.6	5
313	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 712-712.	0.8	5
314	Capecitabine in advanced gastric cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2851-2861.	0.9	4
315	Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP). Annals of Oncology, 2016, 27, vi182.	0.6	4
316	Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. Expert Review of Anticancer Therapy, 2018, 18, 327-338.	1.1	4
317	Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 280-291.	1.8	4
318	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	1.1	4
319	18 Fâ€”choline radiotracer positron emission tomography as a new means to monitor central nervous system lymphoma. British Journal of Haematology, 2021, 193, 1026-1026.	1.2	4
320	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. Blood, 2018, 132, 2892-2892.	0.6	4
321	REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 4057-4057.	0.8	4
322	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. Journal of Clinical Oncology, 2015, 33, TPS4131-TPS4131.	0.8	4
323	PLATFORM: Planning treatment of oesophago-gastric (OG) cancerâ€”A randomised maintenance therapy trial.. Journal of Clinical Oncology, 2016, 34, TPS187-TPS187.	0.8	4
324	CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, TPS4132-TPS4132.	0.8	4

#	ARTICLE	IF	CITATIONS
325	Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.. Journal of Clinical Oncology, 2017, 35, 3-3.	0.8	4
326	Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.. Journal of Clinical Oncology, 2018, 36, TPS4139-TPS4139.	0.8	4
327	Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC) Tj ETQq1 b&784314 rgBT /O		
328	Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 548-548.	0.8	4
329	Abstract 258: MicroRNAs as biomarkers of resistance to HER2 inhibition in combination with chemotherapy in gastro-esophageal cancer. , 2020, , .		4
330	Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment. Leukemia and Lymphoma, 2022, 63, 562-572.	0.6	4
331	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. Cancer Imaging, 2021, 21, 67.	1.2	4
332	Investigational therapies targeting the ErbB family in oesophagogastric cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1349-1363.	1.9	3
333	Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial. Annals of Oncology, 2016, 27, vi220.	0.6	3
334	Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging. Canadian Journal of Cardiology, 2017, 33, 1336.e9-1336.e12.	0.8	3
335	EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers. Annals of Oncology, 2019, 30, v251-v252.	0.6	3
336	MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF). Journal of Thoracic Oncology, 2019, 14, S307.	0.5	3
337	LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy. British Journal of Haematology, 2020, 189, e248-e251.	1.2	3
338	Chronic lymphocytic leukaemia and Richter's transformation: multimodal review and new imaging paradigms. Clinical Radiology, 2021, 76, 789-800.	0.5	3
339	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. Pharmacogenomics, 2021, 22, 703-726.	0.6	3
340	Whole-body diffusion-weighted MRI in lymphoma—comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3549-3561.	1.1	3
341	1416P Genomic landscape of late-stage gastric cancer. Annals of Oncology, 2021, 32, S1062-S1063.	0.6	3
342	A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT).. Journal of Clinical Oncology, 2010, 28, TPS191-TPS191.	0.8	3



#	ARTICLE	IF	CITATIONS
343	JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, TPS4147-TPS4147.	0.8	3
344	<i>RAS</i> mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. Journal of Clinical Oncology, 2014, 32, 489-489.	0.8	3
345	Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. Journal of Clinical Oncology, 2015, 33, 4029-4029.	0.8	3
346	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.. Journal of Clinical Oncology, 2015, 33, 4077-4077.	0.8	3
347	CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, TPS4131-TPS4131.	0.8	3
348	Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.. Journal of Clinical Oncology, 2018, 36, 3059-3059.	0.8	3
349	Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.. Journal of Clinical Oncology, 2018, 36, 401-401.	0.8	3
350	Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.. Journal of Clinical Oncology, 2020, 38, 3089-3089.	0.8	3
351	A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR).. Journal of Clinical Oncology, 2012, 30, TPS4146-TPS4146.	0.8	3
352	Effect of perioperative FLOT <i>versus</i> ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. BJS Open, 2022, 6, .	0.7	3
353	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. Journal of Clinical Oncology, 2022, 40, TPS224-TPS224.	0.8	3
354	Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.. Journal of Clinical Oncology, 2022, 40, 4035-4035.	0.8	3
355	6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer â€“ Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. European Journal of Cancer, 2011, 47, S420-S421.	1.3	2
356	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. Expert Review of Hematology, 2016, 9, 123-135.	1.0	2
357	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2017, 17, 951-964.	1.1	2
358	Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominanty gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital. Annals of Oncology, 2017, 28, iii6.	0.6	2
359	Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. Anticancer Research, 2018, 38, 5943-5949.	0.5	2
360	Clonal diversity of MYC amplification evaluated by fluorescent inÂsitu hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. European Journal of Cancer, 2019, 122, 12-21.	1.3	2

#	ARTICLE	IF	CITATIONS
361	Do investigational MET inhibitors have potential for the treatment of gastric cancer?. Expert Opinion on Investigational Drugs, 2019, 28, 299-302.	1.9	2
362	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. Frontiers in Oncology, 2020, 10, 1634.	1.3	2
363	Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials, 2020, 21, 431.	0.7	2
364	Focal splenic lesions in indolent Bâ€NHL: association with high grade transformation and safe percutaneous biopsy. British Journal of Haematology, 2020, 189, e157-e160.	1.2	2
365	A very rare complication of subdural haematoma: fibrinâ€associated diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2021, 192, 947-947.	1.2	2
366	Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1429-1441.	0.9	2
367	Are treatment response assessment maps (TRAMs) and 18 Fâ€choline positron emission tomography the future of central nervous system lymphoma imaging?. British Journal of Haematology, 2021, 195, e116-e119.	1.2	2
368	1386P Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer. Annals of Oncology, 2021, 32, S1050-S1051.	0.6	2
369	HER-2 in high risk rectal cancer patients treated inÂ€EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2013, 31, 420-420.	0.8	2
370	Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 4067-4067.	0.8	2
371	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. Journal of Clinical Oncology, 2016, 34, TPS178-TPS178.	0.8	2
372	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7537-7537.	0.8	2
373	Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).. Journal of Clinical Oncology, 2017, 35, TPS7579-TPS7579.	0.8	2
374	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. Journal of Clinical Oncology, 2018, 36, e16207-e16207.	0.8	2
375	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 185-189.	1.0	1
376	Nonsurgical Management of Esophageal Adenocarcinoma. Clinical Colorectal Cancer, 2011, 10, 165-170.	1.0	1
377	2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment. European Journal of Cancer, 2015, 51, S446.	1.3	1
378	Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade. Journal of Hepatology, 2016, 64, S693-S694.	1.8	1

#	ARTICLE	IF	CITATIONS
379	Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. <i>Annals of Oncology</i> , 2017, 28, iii139.	0.6	1
380	Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. <i>Annals of Oncology</i> , 2017, 28, iii144-iii145.	0.6	1
381	BACCHUS: A randomised study of neoadjuvant chemotherapy alone in patients with high-risk locally advanced rectal cancer. <i>Annals of Oncology</i> , 2017, 28, iii126.	0.6	1
382	Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD. <i>Annals of Oncology</i> , 2017, 28, iii142-iii143.	0.6	1
383	EGFR amplification (amp) and survival in the REAL-3 trial. <i>Annals of Oncology</i> , 2018, 29, viii217.	0.6	1
384	EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSPHAMIDE, VINCRIStINE, PREDNISOLONE (R-GCVP) IN PATIENTS WITH DLBCL AND CARDIAC COMORBIDITIES. <i>Hematological Oncology</i> , 2019, 37, 425-426.	0.8	1
385	iSCORE: Immunotherapy sequencing in colon and rectal cancer. <i>Annals of Oncology</i> , 2019, 30, v248.	0.6	1
386	Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in. <i>Annals of Oncology</i> , 2019, 30, v254.	0.6	1
387	439P Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2020, 31, S428.	0.6	1
388	Emerging precision therapies for gastric cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 299-311.	0.4	1
389	Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2021, 22, 739-741.	5.1	1
390	Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16074-e16074.	0.8	1
391	Chemotherapy for Advanced Pancreatic Cancer. , 2010, , 913-949.		1
392	Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. <i>Blood</i> , 2014, 124, 1719-1719.	0.6	1
393	A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA4000-LBA4000.	0.8	1
394	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14616-e14616.	0.8	1
395	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 581-581.	0.8	1
396	Outcomes of patients (pts) with BRAF mutated (BRAF MT) Colorectal Cancer (CRC): The Royal Marsden Experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 644-644.	0.8	1

#	ARTICLE	IF	CITATIONS
397	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. Journal of Clinical Oncology, 2017, 35, 2004-2004.	0.8	1
398	Meaningful changes in quality of life (QoL) in patients with gastric cancer: Exploratory analyses from RAINBOW and REGARD.. Journal of Clinical Oncology, 2017, 35, 4047-4047.	0.8	1
399	A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.. Journal of Clinical Oncology, 2017, 35, TPS4138-TPS4138.	0.8	1
400	Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJ) patients from Flatiron Health (FH): Matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032.. Journal of Clinical Oncology, 2018, 36, 51-51.	0.8	1
401	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. Journal of Clinical Oncology, 2018, 36, 90-90.	0.8	1
402	Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJ): A simulated treatment comparison (STC).. Journal of Clinical Oncology, 2019, 37, 128-128.	0.8	1
403	Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice.. Journal of Clinical Oncology, 2012, 30, 603-603.	0.8	1
404	Abstract LB-67: REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line p. , 2013, , .		1
405	Trends in resected oesophageal and gastric adenocarcinoma (OGA) outcomes: Royal Marsden (RM) experience 2001-2010.. Journal of Clinical Oncology, 2015, 33, 169-169.	0.8	1
406	Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data.. Journal of Clinical Oncology, 2015, 33, 4028-4028.	0.8	1
407	iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS221-TPS221.	0.8	1
408	Complications and seeding risk after percutaneous liver biopsy in an oncological setting.. Journal of Clinical Oncology, 2018, 36, 246-246.	0.8	1
409	Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.. Journal of Clinical Oncology, 2018, 36, 4044-4044.	0.8	1
410	Abstract 4339: Molecular subtypes and novel genetic mechanisms of primary and acquired anti-EGFR resistance in colorectal cancer in the Prospect C biomarker trial. , 2018, , .		1
411	CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.. Journal of Clinical Oncology, 2019, 37, 535-535.	0.8	1
412	Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. Journal of Clinical Oncology, 2020, 38, e16537-e16537.	0.8	1
413	Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.. Journal of Clinical Oncology, 2020, 38, 282-282.	0.8	1
414	Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 1089-1107.	1.9	1

#	ARTICLE	IF	CITATIONS
415	P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases. <i>Annals of Oncology</i> , 2020, 31, S134-S135.	0.6	1
416	Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC)., 2019, , .		1
417	Treatment Response Assessment Maps (TRAMs), a new tool for CNS lymphoma. <i>EJHaem</i> , 2022, 3, 247-248.	0.4	1
418	Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	1
419	Aflibercept + FOLFIRI (AF) Versus. Placebo + FOLFIRI (PF) in Metastatic Colorectal Cancer (mCRC): Mean Overall Survival (OS) in a “Better Responders” Patient Population of the Velour Trial. <i>Value in Health</i> , 2013, 16, A397-A398.	0.1	0
420	ANTI-CD30 Antibody Drug Conjugate Therapy in Hodgkin Lymphoma and CD30+ Lymphoma. <i>Annals of Oncology</i> , 2013, 24, ix18.	0.6	0
421	Quality of Life and Bowel Function in Locally Advanced Rectal Cancer Patients Treated with an Intensified Neoadjuvant Regimen in the Expert-C Trial. <i>Annals of Oncology</i> , 2014, 25, iv199.	0.6	0
422	Factors Associated with Second Line Paclitaxel Efficacy in Non-Asian Patients (Pts) with Advanced Oesophagogastric (Og) Cancer. <i>Annals of Oncology</i> , 2014, 25, iv223.	0.6	0
423	Patients' (Pts) Perspectives of Clinical Trials at the Royal Marsden (Rm). <i>Annals of Oncology</i> , 2014, 25, iv485.	0.6	0
424	Designing Therapeutic Trial in Metastatic Gastric Cancer in 2014. <i>Annals of Oncology</i> , 2014, 25, v17.	0.6	0
425	287 The discovery and optimization of small molecule antagonists of the WDR5“MLL interaction. <i>European Journal of Cancer</i> , 2014, 50, 95.	1.3	0
426	2188 Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial. <i>European Journal of Cancer</i> , 2015, 51, S396.	1.3	0
427	P-309 PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC). <i>Annals of Oncology</i> , 2015, 26, iv91.	0.6	0
428	2343 Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD) Tj ETQq0 0 D3gBT /Overlock 10		
429	KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial. <i>Annals of Oncology</i> , 2016, 27, vi173.	0.6	0
430	Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer. <i>Annals of Oncology</i> , 2016, 27, vi215.	0.6	0
431	Platinum-fluoropyrimidine (PF) and paclitaxel (PTX)-based chemotherapy (CT) in advanced anal cancer (AC). <i>Annals of Oncology</i> , 2016, 27, vi166.	0.6	0
432	Investigating the feasibility of precision medicine in gastrointestinal cancers. <i>Annals of Oncology</i> , 2016, 27, vi216.	0.6	0



#	ARTICLE	IF	CITATIONS
433	Chemotherapy for Advanced Pancreatic Cancer. , 2016, , 1-48.		0
434	Colorectal cancer trial endpoints: time for dynamic thinking?. Lancet Oncology, The, 2016, 17, 1345-1347.	5.1	0
435	Heterogeneity of MYC amplification in oesophagogastric (OG) carcinoma: Results from a prospective screening study. Annals of Oncology, 2017, 28, iii2-iii3.	0.6	0
436	Real world use of palliative systemic therapy (tx) in patients (pts) with metastatic early onset colorectal cancer (mEOCRC) within a UK specialist cancer centre. Annals of Oncology, 2017, 28, v202-v203.	0.6	0
437	Chemotherapy for Advanced Pancreatic Cancer. , 2018, , 875-921.		0
438	PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT. Value in Health, 2018, 21, S144.	0.1	0
439	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials. Annals of Oncology, 2018, 29, viii721.	0.6	0
440	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 138-151.	1.0	0
441	The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital. Annals of Oncology, 2019, 30, iv108.	0.6	0
442	Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome. Annals of Oncology, 2019, 30, iv110-iv111.	0.6	0
443	Comparison of Outcomes Between Patients with MYC Rearranged DLBCL and Double/Triple Hit High-Grade B-Cell Lymphoma: A Pan-London Retrospective Review. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S248.	0.2	0
444	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage. Annals of Oncology, 2019, 30, vii5.	0.6	0
445	Early interval and serial positron emission tomography-computed tomography (PET-CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma. British Journal of Haematology, 2020, 190, e357-e362.	1.2	0
446	1446P Initial safety and efficacy findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer. Annals of Oncology, 2020, 31, S909-S910.	0.6	0
447	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	1.1	0
448	453P Routine DPYD mutation testing for patients receiving fluoropyrimidines for gastrointestinal (GI) cancers: Real world experience in a tertiary UK oncology centre. Annals of Oncology, 2021, 32, S559.	0.6	0
449	447P The prognostic factors in early stage BRAF mutant colorectal cancer: Experience from a large volume UK tertiary centre. Annals of Oncology, 2021, 32, S557.	0.6	0
450	1704P Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH) Tj ETQq0 0,0 rgBT /Qoverlock 10	0.6	0



#	ARTICLE	IF	CITATIONS
451	Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?. Bone Marrow Transplantation, 2021, , .	1.3	0
452	A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology, 2010, 28, TPS221-TPS221.	0.8	0
453	Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma.. Journal of Clinical Oncology, 2010, 28, 8052-8052.	0.8	0
454	RCHOPB: Feasibility study of RCHOP plus bevacizumab (B) in patients (pts) with diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2010, 28, TPS304-TPS304.	0.8	0
455	MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors.. Journal of Clinical Oncology, 2010, 28, TPS338-TPS338.	0.8	0
456	Prospective study of genetic mutations in matched tumor and plasma specimens in colorectal cancer patients.. Journal of Clinical Oncology, 2011, 29, 356-356.	0.8	0
457	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2012, 30, e14088-e14088.	0.8	0
458	Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma.. Journal of Clinical Oncology, 2013, 31, 31-31.	0.8	0
459	Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2013, 31, 78-78.	0.8	0
460	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 447-447.	0.8	0
461	Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3.. Journal of Clinical Oncology, 2014, 32, 91-91.	0.8	0
462	The impact of treatment intent on overall survival after radiofrequency ablation of colorectal cancer liver metastases: The Royal Marsden Hospital experience.. Journal of Clinical Oncology, 2014, 32, 622-622.	0.8	0
463	Fifteen-year experience of all patients (pts) with small bowel adenocarcinoma (SBA), treated in a specialized gastrointestinal (GI) oncology unit: Royal Marsden (RM) experience.. Journal of Clinical Oncology, 2014, 32, 316-316.	0.8	0
464	Exclusion of patients with prior cancers from clinical trials: Is this justified?. Journal of Clinical Oncology, 2014, 32, 6544-6544.	0.8	0
465	FC $\hat{\imath}$ <sup>3</sup> R11a and FC $\hat{\imath}$ <sup>3</sup> R11a polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 3573-3573.	0.8	0
466	LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2014, 32, TPS8618-TPS8618.	0.8	0
467	Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin.. Journal of Clinical Oncology, 2014, 32, TPS3653-TPS3653.	0.8	0
468	Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma. Blood, 2014, 124, 3971-3971.	0.6	0

#	ARTICLE	IF	CITATIONS
469	Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [18f]FDG-PET Prior to Allogeneic Transplant. <i>Blood</i> , 2014, 124, 1249-1249.	0.6	0
470	Toxicity and efficacy of salvage paclitaxel chemotherapy in Royal Marsden (RM) oesophagogastric adenocarcinoma (OGA) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015, 33, 188-188.	0.8	0
471	A prospective patient (pt) survey on clinical trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 707-707.	0.8	0
472	Formulating a surveillance strategy following surgery for oesophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 153-153.	0.8	0
473	FOrMAT: Feasibility of a molecular characterization approach to treatment of patients (pts) with advanced gastrointestinal (GI) tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS227-TPS227.	0.8	0
474	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4108-4108.	0.8	0
475	Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial. , 2015, , .		0
476	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. <i>Blood</i> , 2015, 126, 1499-1499.	0.6	0
477	A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.. <i>Journal of Clinical Oncology</i> , 2016, 34, 580-580.	0.8	0
478	The EASI-SWITCH trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS10143-TPS10143.	0.8	0
479	Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases: Implications for targeted treatment.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15027-e15027.	0.8	0
480	Abstract 69: Identification of new therapeutic targets and molecular predictors of response in oesophageal cancer. , 2016, , .		0
481	Chemotherapy for Advanced Pancreatic Cancer. , 2017, , 1-48.		0
482	What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).. <i>Journal of Clinical Oncology</i> , 2018, 36, e16023-e16023.	0.8	0
483	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GE) cancer from the ATTRACTION-2 and CheckMate-032 trials.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15127-e15127.	0.8	0
484	Abstract 4977: MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage. , 2018, , .		0
485	Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience. <i>Blood</i> , 2018, 132, 4240-4240.	0.6	0
486	Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 102-102.	0.8	0

#	ARTICLE	IF	CITATIONS
487	A Phase I/II Dose-Escalation Study of Thiotepe-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial. <i>Blood</i> , 2019, 134, 2879-2879.	0.6	0
488	Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location.. <i>Journal of Clinical Oncology</i> , 2020, 38, 304-304.	0.8	0
489	Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with anti-epidermal growth factor receptor (EGFR) therapy in OZONE.. <i>Journal of Clinical Oncology</i> , 2020, 38, 212-212.	0.8	0
490	SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS471-TPS471.	0.8	0
491	A global phase II trial-in-progress with baviximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS459-TPS459.	0.8	0
492	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 39-51.	1.1	0
493	[18F]Fluoromethylcholine PET/CT for CNS lymphoma assessment: a new tool. <i>F1000Research</i> , 0, 10, 1137.	0.8	0
494	The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
495	Approach to Immunotherapy in Oesophageal Cancer. , 2022, , 31-41.		0
496	Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. <i>Current Oncology</i> , 2022, 29, 2174-2184.	0.9	0
497	Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. <i>Cancer Research</i> , 2022, 82, PR012-PR012.	0.4	0
498	Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. <i>Cancer Research</i> , 2022, 82, A002-A002.	0.4	0